TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03728413

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSV A Memphis 37
Description: Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSV A Memphis 37
Description: Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: RSV A Memphis 37
Description: Subjects will be inoculated using intra-nasal drops with diluted inoculum at a given dose divided equally between the two nostrils. Dose: Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1ml, 25% sucrose/Dulbecco's Modification of Eagle's Medium. Inoculations using intranasal drops will be done using a 1mL pipette with subjects supine. This will be done slowly with sufficient interval between each inoculation (2-3 minutes) to ensure maximum contact time between with the nasal and pharyngeal mucosa. Subjects will be asked not to swallow during the procedure to ensure maximal pharyngeal contact.~Following inoculation, advice regarding hand hygiene will be given, subjects will be provided with alcohol hand gel and facemasks to reduce spread of virus in the environment.
Study: NCT01458223

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic
Description: Ancef or Vancomycin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotic
Description: Ancef or Vancomycin
Study: NCT00031551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02637973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: 25 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily
Study: NCT02675868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressins
Description: Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: NaCl 0.9% infusion
Study: NCT02396043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction phase1
Description: Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8,22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: induction phase2
Description: Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: protocol M
Description: Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: maintenance therapy
Description: 6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reinduction phase1
Description: Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.~Pegaspargase :3750U/m2 im on days 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: reinduction phase2
Description: Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal (IT)
Description: methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
Study: NCT00390585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iodixanol 320
Description: Iodixanol 320 is used as contrast media while coronary intervention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iomeprol 350
Description: Iomeprol 350 is used as contrast media while coronary intervention.
Study: NCT02050152

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Explicit and Implicit memory
Description: Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Explicit and Implicit memory
Description: Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Explicit and Implicit memory
Description: Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide
Study: NCT02037841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing-driven clinical pathway for management of inpatient asthma
Study: NCT02334774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Swallowing and Oral Care Program
Description: An Swallowing and Oral Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
Study: NCT02882724

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 8-week aquatic exercise training program

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control group did not do the exercise training.
Study: NCT03674463

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCAR-B4822M CAR-T Cell Immunotherapy
Description: Patients will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of CAR-T cells. After a pre-treatment lymphodepletion therapy, patients will receive the LCAR-B4822M CAR-T Cell Immunotherapy by intravenous injection.
Study: NCT04758689

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Laser, exercise, and methotrexate
Description: Laser therapy at acupuncture points, aerobic exercise, and methotrexate

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Exercise, and methotrexate
Description: Aerobic exercise, and methotrexate
Study: NCT03171077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation
Description: It is the use of the NW games for rehabilitation of balance in post-stroke patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF Method
Description: It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Rehabilitation and PNF Method
Description: It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
Study: NCT02304796

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Cognitive-Behavioral Therapy
Description: 20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.~The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Cognitive-Behavioral and Dance/Movement Therapy
Description: 20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
Study: NCT01319188

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg of ranibizumab
Description: Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 0.5 mg of ranibizumab + photodynamic therapy
Description: Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham injection
Description: Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
Study: NCT02680002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 mcg H5N1 (stored as monobulk)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7.5 mcg H5N1 (stored as monobulk)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 mcg H5N1 (stored as monobulk)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 mcg H5N1 (stored as monobulk)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 mcg H5N1 (stored as monobulk)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 90 mcg H5N1 (stored in vials)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59 (stored as monobulk)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MF59 (stored as monobulk)
Study: NCT03572478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600 mg taken by mouth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600 mg taken by mouth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 600 mg taken by mouth twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg given by intravenous (IV) infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg given by intravenous (IV) infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 480 mg given by intravenous (IV) infusion every 4 weeks.
Study: NCT03527173

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S.sonnei vaccine
Description: Subjects receiving 2 doses of the study vaccine by intramuscular route, 28 days apart (at Day 1 and Day 29).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects receiving 2 doses of placebo by intramuscular route, 28 days apart (at Day 1 and Day 29).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: S. sonnei 53G challenge strain
Description: Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: S. sonnei 53G challenge strain
Description: Subjects receiving the challenge dose of S. sonnei 53G strain, orally, at Day 57.
Study: NCT03790319

Intervention type: BEHAVIORAL
Intervention: The Power of Feelings
Description: Three workshops of three days each teach about the five basic feelings rage, sadness, fear, shame and joy and talk about the powerful and destructive qualities they can have. In addition to that they are about how to deal with emotions, which are defined as unfelt feelings of the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion.

Intervention type: BEHAVIORAL
Intervention: The Emotional Backpack
Description: One workshop of three days teach about how to deal with emotions, which are defined as unfelt feelings of the past. They show a way to work in couples with a form of emotional disclosure that helps process emotions that have been overwhelming in the past.~Smaller lectures give the participants an overview about the themes. Through exercises the participants can make experiences p.e. about each of the feelings. Another element is the sharing in dyads or small groups about actual feelings to practice emotional disclosure and to build a culture of openness and compassion.
Study: NCT03818685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Radiotherapy will be maintained in each Arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Radiotherapy will be maintained in each Arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Radiotherapy will be maintained in each Arm.
Study: NCT03701815

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellness in Rehabilitation program
Description: The 12-week Wellness in Rehabilitation program includes weekly in-person meetings including aerobic exercise, nutrition/cooking training, stress management techniques, education, and group support. A health coach will facilitate continuation of healthy behaviors at home.
Study: NCT00504660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.
Study: NCT03755258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 100 mg + Placebo 200 mg
Description: GCK 100 mg + Placebo 200 mg, oral, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 200 mg + Placebo 100 mg
Description: GCK 200 mg + Placebo 100 mg, oral, 12 weeks
Study: NCT00504660

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Arms 1,3 = 825 mg/m\^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m\^2 PO Every 12 Hours on Day 11-24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib (Celebrex)
Description: Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Arms 1,3 = 150 mg/m\^2 PO Daily On Day 4-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Arms 2,3 = 100 mg/m\^2 PO on Day 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lomustine
Description: Arms 2,3 = 100 mg/m\^2 PO on Day 4.
Study: NCT03755258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCK 300 mg
Description: GCK 300 mg, oral, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 300mg
Description: Placebo 300mg, oral, 12 weeks
Study: NCT01178047

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rasagiline
Description: Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rasagiline
Description: Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
Study: NCT03217604

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment with placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06852231
Description: Treatment with PF-06852231
Study: NCT00535496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
Study: NCT01843621

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DEN vaccine F17
Description: The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
Study: NCT03606369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: Palonosetron 0.25 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV for early emesis and for delayed emesis Dexamethasone 8 mg orally on days 2, 3 and 4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Early emesis: Ondansetron 16 mg IV + Dexamethasone 12 mg IV + Fosaprepitant 150 mg IV. and for delayed emesis: Metoclopramide 10 mg orally every 6 hours + Dexamethasone 8 mg orally every 24 hrs.
Study: NCT00732030

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toric IOL (SN60T3)
Description: Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
Study: NCT02887677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
Study: NCT01853670

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: concurrent chemo + IGRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemo + IGRT
Study: NCT00071890

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin 2
Description: Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: HAART from week 0 to week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: HAART from week 0 to week 24

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment interruption
Description: HAART is interrupted from week 24 in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment interruption
Description: HAART is interrupted from week 24 in both arms